Asparagine-betahydroxylase (ASPH) plays an important role in cell growth, differentiation, adhesion and migration. And ASPH is silent in adult tissues in normal. It expresses at very low levels or not expresses at all in most normal cells and tissues. High level of ASPH always be detected in aggressive tumor cells and it indicates worsened clinical prognosis. The expression of ASPH in paraffin-embedded tissue sections was detected by immunostaining. We analyzed the distributions and levels of ASPH by immunohistochemical staining in breast cancer. ASPH is expressed high in breast cancer. And we detected the expression of ASPH by Elisa in breast cancer cells (MCF7) and normal mammary epithelial cells (MCF10A). The level of ASPH is higher in MCF7 than MCF10A. In breast cancer, the ASPH positive cases are 15 of 34, and the positive rate is 44.1%. The higher grade cancer was associated with the higher levels of ASPH. And we found that the ASPH expression have relation to the expression of progesterone receptor (PR) and HER-2. Our study demonstrates that increased ASPH expression in breast cancer, and it has closed relation to the level of PR and HER-2. Therefore, ASPH may be closely related to the malignant degree and prognosis of breast cancer.
| Published in | American Journal of Biomedical and Life Sciences (Volume 10, Issue 4) |
| DOI | 10.11648/j.ajbls.20221004.12 |
| Page(s) | 110-115 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
ASPH, Breast Cancer, ER, PR, Her-2
| [1] | Chung, W., M. Kim, S. dela Monte, L. Longato, R. Carlson, B. L. Slagle, X. Dong, and J. R. Wands, Activation of signal transduction pathways during hepatic oncogenesis. Cancer Lett, 2016. 370 (1): p. 1-9. |
| [2] | Jia, S., W. J. Van Dusen, R. E. Diehl, N. E. Kohl, R. A. Dixon, K. O. Elliston, A. M. Stern, and P. A. Friedman, cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem, 1992. 267 (20): p. 14322-7. |
| [3] | Aihara, A., C. K. Huang, M. J. Olsen, Q. Lin, W. Chung, Q. Tang, X. Dong, and J. R. Wands, A cell-surface beta-hydroxylase is a biomarker and the rapeutic target for hepato cellular carcinoma. Hepatology, 2014. 60 (4): p. 1302-13. |
| [4] | Luu, M., E. Sabo, S. M. dela Monte, W. Greaves, J. Wang, R. Tavares, L. Simao, J. R. Wands, M. B. Resnick, and L. Wang, Prognostic value of aspartyl (asparaginyl) - beta- hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol, 2009. 40 (5): p. 639-44. |
| [5] | Dong, X., Q. Lin, A. Aihara, Y. Li, C. K. Huang, W. Chung, Q. Tang, X. Chen, R. Carlson, C. Nadolny, G. Gabriel, M. Olsen, and J. R. Wands, Aspartatebeta-Hydroxylase expression promotes a malignant pancreatic cellular phenotype. Oncotarget, 2015. 6 (2): p. 1231-48. |
| [6] | Ghanbari, H. A., Cancer Diagnostics Integrated With The rapeutics: A Comprehensive Approach to Managing the Disease. J Biomed Biotechnol, 2004. 2004 (4): p. 175-176. |
| [7] | Xu, L., Y. Ma, H. Zhang, Q. J. Lu, L. Yang, G. N. Jiang, and W. L. Liao, HMGA 2 regulates circular RNA ASPH to promote tumor growth in lung adenocarcinoma. Cell Death Dis, 2020. 11 (7): p. 593. |
| [8] | Dinchuk, J. E., N. L. Henderson, T. C. Burn, R. Huber, S. P. Ho, J. Link, K. T. O' Neil, R. J. Focht, M. S. Scully, J. M. Hollis, G. F. Hollis, and P. A. Friedman, Aspartyl beta-hydroxylase (Asph) and an evolutionarily conserved isoform of Asphmissing the catalytic domain share exons with junctin. J Biol Chem, 2000. 275 (50): p. 39543-54. |
| [9] | Treves, S., G. Feriotto, L. Moccagatta, R. Gambari, and F. Zorzato, Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco (endo) plasmic reticulum membrane. J Biol Chem, 2000. 275 (50): p. 39555-68. |
| [10] | Zheng, W., X. Wang, J. Hu, B. Bai, and H. Zhu, Diverse molecular functions of aspartate beta hydroxylase in cancer (Review). Oncol Rep, 2020. 44 (6): p. 2364-2372. |
| [11] | Ogawa, K., Q. Lin, L. Li, X. Bai, X. Chen, H. Chen, R. Kong, Y. Wang, H. Zhu, F. He, Q. Xu, L. Liu, M. Li, S. Zhang, K. Nagaoka, R. Carlson, H. Safran, K. Charpentier, B. Sun, J. Wands, and X. Dong, Aspartate beta- hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. J Hematol Oncol, 2019. 12 (1): p. 144. |
| [12] | Duffy, M. J., N. Harbeck, M. Nap, R. Molina, A. Nicolini, E. Senkus, and F. Cardoso, Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer, 2017. 75: p. 284-298. |
| [13] | Colleoni, M. and E. Montagna, Neoadjuvant therapy for ER-positive breast cancers. Ann Oncol, 2012. 23 Suppl 10: p. x 243-8. |
| [14] | Early Breast Cancer Trialists' Collaborative, G., C. Davies, J. Godwin, R. Gray, M. Clarke, D. Cutter, S. Darby, P. McGale, H. C. Pan, C. Taylor, Y. C. Wang, M. Dowsett, J. Ingle, and R. Peto, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-levelmeta-analysis of randomised trials. Lancet, 2011. 378 (9793): p. 771-84. |
| [15] | Rugo, H. S., R. B. Rumble, E. Macrae, D. L. Barton, H. K. Connolly, M. N. Dickler, L. Fallowfield, B. Fowble, J. N. Ingle, M. Jahanzeb, S. R. Johnston, L. A. Korde, J. L. Khatcheressian, R. S. Mehta, H. B. Muss, and H. J. Burstein, Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol, 2016. 34 (25): p. 3069-103. |
| [16] | VanBelle, V., B. Van Calster, O. Brouckaert, I. Vanden Bempt, S. Pintens, V. Harvey, P. Murray, B. Naume, G. Wiedswang, R. Paridaens, P. Moerman, F. Amant, K. Leunen, A. Smeets, M. Drijkoningen, H. Wildiers, M. R. Christiaens, I. Vergote, S. Van Huffel, and P. Neven, Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. J Clin Oncol, 2010. 28 (27): p. 4129-34. |
| [17] | Salmen, J., J. Neugebauer, P. A. Fasching, L. Haeberle, J. Huober, A. Wockel, C. Rauh, F. Schuetz, T. Weissenbacher, B. Kost, E. Stickeler, M. Klar, M. Orlowska-Volk, M. Windfuhr-Blum, J. Heil, J. Rom, C. Sohn, T. Fehm, S. Mohrmann, C. R. Loehberg, A. Hein, R. Schulz-Wendtland, A. D. Hartkopf, S. Y. Brucker, D. Wallwiener, K. Friese, A. Hartmann, M. W. Beckmann, W. Janni, and B. Rack, Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat, 2014. 148 (1): p. 143-51. |
| [18] | Hammond, M. E., D. F. Hayes, M. Dowsett, D. C. Allred, K. L. Hagerty, S. Badve, P. L. Fitzgibbons, G. Francis, N. S. Goldstein, M. Hayes, D. G. Hicks, S. Lester, R. Love, P. B. Mangu, L. McShane, K. Miller, C. K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J. N. Schwartz, F. C. Sweep, S. Taube, E. E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. B. Williams, J. L. Wittliff, and A. C. Wolff, American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 2010. 28 (16): p. 2784-95. |
| [19] | Harbeck, N. and M. Gnant, Breast cancer. Lancet, 2017. 389 (10074): p. 1134-1150. |
| [20] | Patel, N., A. O. Khan, A. Mansour, J. Y. Mohamed, A. Al-Assiri, R. Haddad, X. Jia, Y. Xiong, A. Megarbane, E. I. Traboulsi, and F. S. Alkuraya, Mutations in ASPH cause facial dysmorphism, lens dislocation, anterior-segment abnormalities, and spontaneous filtering blebs, or Traboulsi syndrome. Am J Hum Genet, 2014. 94 (5): p. 755-9. |
| [21] | Wang, K., J. Liu, Z. L. Yan, J. Li, L. H. Shi, W. M. Cong, Y. Xia, Q. F. Zou, T. Xi, F. Shen, H. Y. Wang, and M. C. Wu, Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepato cellular carcinoma is associated with worse surgical outcome. Hepatology, 2010. 52 (1): p. 164-73. |
| [22] | Hou, G., B. Xu, Y. Bi, C. Wu, B. Ru, B. Sun, and X. Bai, Recent advances in research on aspartatebeta-hydroxylase (ASPH) in pancreatic cancer: Abriefupdate. Bosn J Basic MedSci, 2018. 18 (4): p. 297-304. |
| [23] | delaMonte, S. M., S. Tamaki, M. C. Cantarini, N. Ince, M. Wiedmann, J. J. Carter, S. A. Lahousse, S. Califano, T. Maeda, T. Ueno, A. D'Errico, F. Trevisani, and J. R. Wands, Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepato cellular carcinoma invasiveness. J Hepatol, 2006. 44 (5): p. 971-83. |
| [24] | Jia, Y., Y. Lu, K. Wu, Q. Lin, W. Shen, M. Zhu, S. Huang, and J. Chen, Does nightwork increase the risk of breast cancer? A systematic review and meta-analysis of epidemiological studies. Cancer Epidemiol, 2013. 37 (3): p. 197-206. |
| [25] | Li, J., B. N. Zhang, J. H. Fan, Y. Pang, P. Zhang, S. L. Wang, S. Zheng, B. Zhang, H. J. Yang, X. M. Xie, Z. H. Tang, H. Li, J. Y. Li, J. J. He, and Y. L. Qiao, Anation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer, 2011. 11: p. 364. |
| [26] | Ivkovic-Kapicl, T., S. Knezevic-Usaj, D. Djilas-Ivanovic, and M. Panjkovic, Correlation of HER-2/neuprotein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. In Vivo, 2007. 21 (4): p. 673-8. |
| [27] | Hammond, M. E., D. F. Hayes, A. C. Wolff, P. B. Mangu, and S. Temin, American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract, 2010. 6 (4): p. 195-7. |
| [28] | Coates, A. S., E. P. Winer, A. Goldhirsch, R. D. Gelber, M. Gnant, M. Piccart-Gebhart, B. Thurlimann, H. J. Senn, and M. Panel, Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol, 2015. 26 (8): p. 1533-46. |
| [29] | Ades F., D. Zardavas, I. Bozovic-Spasojevic, L. Pugliano, D. Fumagalli, E. deAzambuja, G. Viale, C. Sotiriou, and M. Piccart, Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol, 2014. 32 (25): p. 2794-803. |
| [30] | Shimoda, M., A. Hori, J. R. Wands, R. Tsunashima, Y. Naoi, T. Miyake, T. Tanei, N. Kagara, K. Shimazu, S. J. Kim, and S. Noguchi, Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-beta-hydroxylase expression. Cancer Sci, 2017. 108 (12): p. 2454-2461. |
APA Style
Zhao Xiaofeng, Qin Xuying, Yin Linlin, Chen Dong, Zheng Juan. (2022). The Expression of ASPH in Breast Cancer. American Journal of Biomedical and Life Sciences, 10(4), 110-115. https://doi.org/10.11648/j.ajbls.20221004.12
ACS Style
Zhao Xiaofeng; Qin Xuying; Yin Linlin; Chen Dong; Zheng Juan. The Expression of ASPH in Breast Cancer. Am. J. Biomed. Life Sci. 2022, 10(4), 110-115. doi: 10.11648/j.ajbls.20221004.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajbls.20221004.12,
author = {Zhao Xiaofeng and Qin Xuying and Yin Linlin and Chen Dong and Zheng Juan},
title = {The Expression of ASPH in Breast Cancer},
journal = {American Journal of Biomedical and Life Sciences},
volume = {10},
number = {4},
pages = {110-115},
doi = {10.11648/j.ajbls.20221004.12},
url = {https://doi.org/10.11648/j.ajbls.20221004.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20221004.12},
abstract = {Asparagine-betahydroxylase (ASPH) plays an important role in cell growth, differentiation, adhesion and migration. And ASPH is silent in adult tissues in normal. It expresses at very low levels or not expresses at all in most normal cells and tissues. High level of ASPH always be detected in aggressive tumor cells and it indicates worsened clinical prognosis. The expression of ASPH in paraffin-embedded tissue sections was detected by immunostaining. We analyzed the distributions and levels of ASPH by immunohistochemical staining in breast cancer. ASPH is expressed high in breast cancer. And we detected the expression of ASPH by Elisa in breast cancer cells (MCF7) and normal mammary epithelial cells (MCF10A). The level of ASPH is higher in MCF7 than MCF10A. In breast cancer, the ASPH positive cases are 15 of 34, and the positive rate is 44.1%. The higher grade cancer was associated with the higher levels of ASPH. And we found that the ASPH expression have relation to the expression of progesterone receptor (PR) and HER-2. Our study demonstrates that increased ASPH expression in breast cancer, and it has closed relation to the level of PR and HER-2. Therefore, ASPH may be closely related to the malignant degree and prognosis of breast cancer.},
year = {2022}
}
TY - JOUR T1 - The Expression of ASPH in Breast Cancer AU - Zhao Xiaofeng AU - Qin Xuying AU - Yin Linlin AU - Chen Dong AU - Zheng Juan Y1 - 2022/07/28 PY - 2022 N1 - https://doi.org/10.11648/j.ajbls.20221004.12 DO - 10.11648/j.ajbls.20221004.12 T2 - American Journal of Biomedical and Life Sciences JF - American Journal of Biomedical and Life Sciences JO - American Journal of Biomedical and Life Sciences SP - 110 EP - 115 PB - Science Publishing Group SN - 2330-880X UR - https://doi.org/10.11648/j.ajbls.20221004.12 AB - Asparagine-betahydroxylase (ASPH) plays an important role in cell growth, differentiation, adhesion and migration. And ASPH is silent in adult tissues in normal. It expresses at very low levels or not expresses at all in most normal cells and tissues. High level of ASPH always be detected in aggressive tumor cells and it indicates worsened clinical prognosis. The expression of ASPH in paraffin-embedded tissue sections was detected by immunostaining. We analyzed the distributions and levels of ASPH by immunohistochemical staining in breast cancer. ASPH is expressed high in breast cancer. And we detected the expression of ASPH by Elisa in breast cancer cells (MCF7) and normal mammary epithelial cells (MCF10A). The level of ASPH is higher in MCF7 than MCF10A. In breast cancer, the ASPH positive cases are 15 of 34, and the positive rate is 44.1%. The higher grade cancer was associated with the higher levels of ASPH. And we found that the ASPH expression have relation to the expression of progesterone receptor (PR) and HER-2. Our study demonstrates that increased ASPH expression in breast cancer, and it has closed relation to the level of PR and HER-2. Therefore, ASPH may be closely related to the malignant degree and prognosis of breast cancer. VL - 10 IS - 4 ER -
Email: